SenesTech Inc (NASDAQ:SNES) traded down 4.3% on Monday . The stock traded as low as $1.60 and last traded at $1.56. 3,022 shares changed hands during trading, a decline of 100% from the average session volume of 2,161,867 shares. The stock had previously closed at $1.63.
A number of equities research analysts have recently commented on SNES shares. Zacks Investment Research upgraded SenesTech from a “sell” rating to a “hold” rating in a research report on Wednesday, June 20th. ValuEngine upgraded SenesTech from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd. Finally, Roth Capital restated a “buy” rating on shares of SenesTech in a research report on Wednesday, April 4th.
The company has a quick ratio of 4.89, a current ratio of 5.65 and a debt-to-equity ratio of 0.10. The stock has a market cap of $27.16 million, a P/E ratio of -1.41 and a beta of 3.53.
SenesTech (NASDAQ:SNES) last posted its earnings results on Monday, May 14th. The company reported ($0.16) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.01). SenesTech had a negative net margin of 17,962.50% and a negative return on equity of 205.29%. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.25 million. research analysts forecast that SenesTech Inc will post -0.5 EPS for the current year.
A hedge fund recently bought a new stake in SenesTech stock. Sabby Management LLC bought a new stake in shares of SenesTech Inc (NASDAQ:SNES) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 436,863 shares of the company’s stock, valued at approximately $315,000. Sabby Management LLC owned 2.77% of SenesTech as of its most recent SEC filing. Institutional investors own 21.92% of the company’s stock.
SenesTech Company Profile
SenesTech, Inc develops a technology for managing animal pest populations through fertility control. The company focuses on commercializing ContraPest, a fertility control product for use in controlling rat populations. It is also developing a pipeline of fertility control and animal health products, including feral animal fertility control, non-surgical spay and neutering, boar taint, and animal cancer treatment.
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.